PDCD1 and cancer: Considering the ability of HITT to respond to IFN-γ signals and the improved response of HITT-overexpressing cancer cells or tumors to anti–PD-1 treatment, it is worth investigating whether HITT can predict response to anti–PD-1/PD-L1 treatment in future studies.